Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke Akard

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|September 21, 2012
Eltrombopag in refractory aplastic anemiaLuke Akard
Current Hematologic Malignancy Reports|February 29, 2016
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaLauren Caldemeyer, Michael Dugan, John Edwards, et al.
Leukemia & Lymphoma|March 22, 2014
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitorsH Jean Khoury, Jorge Cortes, Michele Baccarani, et al.
Haematologica|June 12, 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitorsFranck E Nicolini, H Jean Khoury, Luke Akard, et al.
Leukemia & Lymphoma|October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinateLuke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinibJorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responsesJorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysisHillard M Lazarus, Patrick J Stiff, Jeanette Carreras, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Cancer|January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-upJorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|September 21, 2012
Eltrombopag in refractory aplastic anemiaLuke Akard
Current Hematologic Malignancy Reports|February 29, 2016
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaLauren Caldemeyer, Michael Dugan, John Edwards, et al.
Leukemia & Lymphoma|March 22, 2014
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitorsH Jean Khoury, Jorge Cortes, Michele Baccarani, et al.
Haematologica|June 12, 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitorsFranck E Nicolini, H Jean Khoury, Luke Akard, et al.
Leukemia & Lymphoma|October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinateLuke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinibJorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responsesJorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysisHillard M Lazarus, Patrick J Stiff, Jeanette Carreras, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Cancer|January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-upJorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
Pageof 2